2013
Transcranial Magnetic Stimulation of Wernicke’s and Right Homologous Sites to Curtail “Voices”: A Randomized Trial
Hoffman RE, Wu K, Pittman B, Cahill JD, Hawkins KA, Fernandez T, Hannestad J. Transcranial Magnetic Stimulation of Wernicke’s and Right Homologous Sites to Curtail “Voices”: A Randomized Trial. Biological Psychiatry 2013, 73: 1008-1014. PMID: 23485015, PMCID: PMC3641174, DOI: 10.1016/j.biopsych.2013.01.016.Peer-Reviewed Original Research
2010
Neuropsychology of the Prodrome to Psychosis in the NAPLS Consortium: Relationship to Family History and Conversion to Psychosis
Seidman LJ, Giuliano AJ, Meyer EC, Addington J, Cadenhead KS, Cannon TD, McGlashan TH, Perkins DO, Tsuang MT, Walker EF, Woods SW, Bearden CE, Christensen BK, Hawkins K, Heaton R, Keefe RS, Heinssen R, Cornblatt BA. Neuropsychology of the Prodrome to Psychosis in the NAPLS Consortium: Relationship to Family History and Conversion to Psychosis. JAMA Psychiatry 2010, 67: 578-588. PMID: 20530007, PMCID: PMC3332118, DOI: 10.1001/archgenpsychiatry.2010.66.Peer-Reviewed Original ResearchConceptsFamily historyCHR individualsNeuropsychological functioningCHR syndromeNorth American Prodrome Longitudinal StudyClinical high-risk individualsHigh-risk groupFirst-episode schizophreniaBaseline neuropsychological evaluationHigh-risk individualsSecond-degree relativesHigh-risk statusLongitudinal studyGlobal neuropsychological functioningWorse verbal memoryPrediction of psychosisCHR assessmentSyndrome criteriaProspective evaluationClinical criteriaModerate severityNeurocognitive composite scorePsychosis onsetNormal controlsSubsequent psychosis
2009
Endophenotypes in schizophrenia: A selective review
Allen AJ, Griss ME, Folley BS, Hawkins KA, Pearlson GD. Endophenotypes in schizophrenia: A selective review. Schizophrenia Research 2009, 109: 24-37. PMID: 19223268, PMCID: PMC2665704, DOI: 10.1016/j.schres.2009.01.016.Peer-Reviewed Original Research
2008
Neuropsychological course in the prodrome and first episode of psychosis: Findings from the PRIME North America Double Blind Treatment Study
Hawkins KA, Keefe RS, Christensen BK, Addington J, Woods SW, Callahan J, Zipursky RB, Perkins DO, Tohen M, Breier A, McGlashan TH. Neuropsychological course in the prodrome and first episode of psychosis: Findings from the PRIME North America Double Blind Treatment Study. Schizophrenia Research 2008, 105: 1-9. PMID: 18774696, DOI: 10.1016/j.schres.2008.07.008.Peer-Reviewed Original ResearchConceptsNeuropsychological courseDouble-blind treatment studyNeuropsychological StatusPlacebo-assigned subjectsPutative prodromal stateDouble-blind trialFrank psychotic episodeEarly convertersOlanzapine treatmentNeuropsychological deficienciesFrank psychosisMedication studiesFirst episodePsychotic episodeProdromal stateHigh riskBlind trialNeuropsychological declineTreatment studiesPsychotic conditionsPsychosisLate convertersOlanzapineProdromeInitial assessment
2007
Extracting spurious messages from noise and risk of schizophrenia-spectrum disorders in a prodromal population
Hoffman RE, Woods SW, Hawkins KA, Pittman B, Tohen M, Preda A, Breier A, Glist J, Addington J, Perkins DO, McGlashan TH. Extracting spurious messages from noise and risk of schizophrenia-spectrum disorders in a prodromal population. The British Journal Of Psychiatry 2007, 191: 355-356. PMID: 17906248, DOI: 10.1192/bjp.bp.106.031195.Peer-Reviewed Original ResearchConceptsSchizophrenia spectrum disordersTime-dependent Cox regression analysisCox regression analysisMedication-free intervalOlanzapine treatmentPlacebo groupPharmacological treatmentProdromal symptomsRisk factorsProdromal populationSpeech illusionsDisordersRegression analysisYear 2TreatmentSignificant interactionYear 1SymptomsProbing the Pathophysiology of Auditory/Verbal Hallucinations by Combining Functional Magnetic Resonance Imaging and Transcranial Magnetic Stimulation
Hoffman RE, Hampson M, Wu K, Anderson AW, Gore JC, Buchanan RJ, Constable RT, Hawkins KA, Sahay N, Krystal JH. Probing the Pathophysiology of Auditory/Verbal Hallucinations by Combining Functional Magnetic Resonance Imaging and Transcranial Magnetic Stimulation. Cerebral Cortex 2007, 17: 2733-2743. PMID: 17298962, PMCID: PMC2634833, DOI: 10.1093/cercor/bhl183.Peer-Reviewed Original ResearchConceptsRepetitive transcranial magnetic stimulationTranscranial magnetic stimulationFunctional magnetic resonance imagingMagnetic resonance imagingMagnetic stimulationSham stimulationTemporoparietal repetitive transcranial magnetic stimulationAuditory/verbal hallucinationsResonance imagingWernicke's areaVerbal hallucinationsBOLD signal time coursesBroca's areaSchizophrenia spectrum disordersGreater rateInferior frontal regionsPatientsTemporoparietal areasSignal time courseCortical sitesPathophysiologySupramarginal gyrusHallucinationsRight homologueStimulation
2006
Randomized, Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis
McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, Hawkins KA, Hoffman RE, Preda A, Epstein I, Addington D, Lindborg S, Trzaskoma Q, Tohen M, Breier A. Randomized, Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis. American Journal Of Psychiatry 2006, 163: 790-799. PMID: 16648318, DOI: 10.1176/ajp.2006.163.5.790.Peer-Reviewed Original ResearchConceptsOlanzapine patientsPlacebo patientsProdromal symptomsPsychosis ratesDouble-blind treatment periodEfficacy of olanzapineFurther treatment researchOlanzapine Versus PlaceboOlanzapine-treated patientsDouble-blind trialPhase of illnessPositive prodromal symptomsInduced Weight GainHazard of conversionSignificant differencesNorth American clinicsSignificant treatment differencesOlanzapine groupVersus PlaceboPlacebo groupSymptom scoresEfficacy measuresWeek 8Treatment periodPatients
2004
Factorial structure of the Scale of Prodromal Symptoms
Hawkins KA, McGlashan TH, Quinlan D, Miller TJ, Perkins DO, Zipursky RB, Addington J, Woods SW. Factorial structure of the Scale of Prodromal Symptoms. Schizophrenia Research 2004, 68: 339-347. PMID: 15099615, DOI: 10.1016/s0920-9964(03)00053-7.Peer-Reviewed Original ResearchNeuropsychological status of subjects at high risk for a first episode of psychosis
Hawkins KA, Addington J, Keefe RS, Christensen B, Perkins DO, Zipurksy R, Woods SW, Miller TJ, Marquez E, Breier A, McGlashan TH. Neuropsychological status of subjects at high risk for a first episode of psychosis. Schizophrenia Research 2004, 67: 115-122. PMID: 14984870, DOI: 10.1016/j.schres.2003.08.007.Peer-Reviewed Original ResearchConceptsFirst episodeFirst psychotic episodeLevel of impairmentSchizophrenia prodromePsychotic episodeHigh riskMulti-site studyProdromal interventionPopulation normsNeuropsychological examNeuropsychological StatusNeuropsychological functioningNormal intelligenceEpisodesSchizophrenia samplePsychosisSubjectsRiskStatusProdromeSchizophreniaImpairmentSeverity
2003
Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome
Woods SW, Breier A, Zipursky RB, Perkins DO, Addington J, Miller TJ, Hawkins KA, Marquez E, Lindborg SR, Tohen M, McGlashan TH. Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry 2003, 54: 453-464. PMID: 12915290, DOI: 10.1016/s0006-3223(03)00321-4.Peer-Reviewed Original ResearchConceptsExtrapyramidal symptomsPlacebo-controlled trialShort-term efficacyTrial of olanzapineTreatment x time interactionGreater symptomatic improvementSymptom total scoreX time interactionGreater weight gainRepeated-measures analysisOlanzapine patientsSchizophrenic prodromeOlanzapine treatmentPlacebo patientsSymptomatic improvementAcute treatmentMore patientsOlanzapine 5Prodromal symptomsRoutine treatmentProdromal patientsProdromal phaseWeek 8Week 6PlaceboThe PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis II. Baseline characteristics of the “prodromal” sample
Miller TJ, Zipursky RB, Perkins D, Addington J, Woods SW, Hawkins KA, Hoffman R, Preda A, Epstein I, Addington D, Lindborg S, Marquez E, Tohen M, Breier A, McGlashan TH. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis II. Baseline characteristics of the “prodromal” sample. Schizophrenia Research 2003, 61: 19-30. PMID: 12648732, DOI: 10.1016/s0920-9964(02)00440-1.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntipsychotic AgentsBenzodiazepinesBipolar DisorderComorbidityDepressive Disorder, MajorDouble-Blind MethodFemaleHumansMaleMood DisordersOlanzapinePirenzepinePsychomotor DisordersPsychotic DisordersRisk FactorsSchizophreniaSchizophrenic PsychologySleep Wake DisordersSpeech DisordersConceptsFirst-episode schizophreniaEpisode schizophreniaTreatment-seeking patientsClinical trialsDouble-blind placebo-controlled clinical trialProdromal SyndromesDouble-blind clinical trialPlacebo-controlled clinical trialAtypical neuroleptic medicationsMild affective symptomsNew diagnostic criteriaSerious mental illnessClinical trial samplesUntreated first-episode schizophreniaSubstance use/abuseEffects of drugsPutative prodromal syndromeUse/abuseUnusual thought contentAdolescent maniaOngoing symptomatologyProdromal sampleStudy medicationBaseline characteristicsMost patientsThe PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis I. Study rationale and design
McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller TJ, Woods SW, Hawkins KA, Hoffman R, Lindborg S, Tohen M, Breier A. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis I. Study rationale and design. Schizophrenia Research 2003, 61: 7-18. PMID: 12648731, DOI: 10.1016/s0920-9964(02)00439-5.Peer-Reviewed Original ResearchConceptsPsychosis onsetClinical trialsDouble-blind placebo-controlled clinical trialStudy rationaleDouble-blind clinical trialPlacebo-controlled clinical trialAtypical neuroleptic medicationsNew diagnostic criteriaClinical trial designPutative prodromal syndromeTreatment-seeking patientsOngoing symptomatologyNeuroleptic medicationHigh riskDiagnostic criteriaTrial designEarly courseProdromal SyndromesClinical phenomenologyStudy designClinical populationsPatientsOnsetIntervention researchTrialsTranscranial Magnetic Stimulation of Left Temporoparietal Cortex and Medication-Resistant Auditory Hallucinations
Hoffman RE, Hawkins KA, Gueorguieva R, Boutros NN, Rachid F, Carroll K, Krystal JH. Transcranial Magnetic Stimulation of Left Temporoparietal Cortex and Medication-Resistant Auditory Hallucinations. JAMA Psychiatry 2003, 60: 49-56. PMID: 12511172, DOI: 10.1001/archpsyc.60.1.49.Peer-Reviewed Original ResearchConceptsRepetitive transcranial magnetic stimulationMedication-resistant auditory hallucinationsTranscranial magnetic stimulationLeft temporoparietal cortexAuditory hallucinationsSham stimulationMagnetic stimulationTemporoparietal cortexOpen-label trialMotor thresholdAntipsychotic medicationSustained reductionBrain areasSchizoaffective disorderCortical activationPossible treatmentNeuropsychological impairmentNeuropsychological assessmentPatientsAdditional studiesCortexStimulationTrialsHallucinationsTreatment effects
2001
Estimated yield of early detection of prodromal or first episode patients by screening first degree relatives of schizophrenic patients
Woods S, Miller T, Davidson L, Hawkins K, Sernyak M, McGlashan T. Estimated yield of early detection of prodromal or first episode patients by screening first degree relatives of schizophrenic patients. Schizophrenia Research 2001, 52: 21-27. PMID: 11595388, DOI: 10.1016/s0920-9964(01)00158-x.Peer-Reviewed Original ResearchConceptsPopulation of relativesSchizophrenic patientsIntervention studiesNew casesEarly first episodeFirst-episode patientsChildren of patientsFirst-degree relativesEarly intervention studiesEpisode patientsLifetime riskProdromal patientsDegree relativesRisk groupsFirst episodeCurrent patientsPatientsRisk relativesSchizophrenic probandsEarly detectionSchizophrenia casesSchizophreniaAge distributionOnset distributionProbandsUse of the Medication Event Monitoring System to estimate medication compliance in patients with schizophrenia.
Diaz E, Levine HB, Sullivan MC, Sernyak MJ, Hawkins KA, Cramer JA, Woods SW. Use of the Medication Event Monitoring System to estimate medication compliance in patients with schizophrenia. Journal Of Psychiatry And Neuroscience 2001, 26: 325-9. PMID: 11590972, PMCID: PMC167186.Peer-Reviewed Original ResearchConceptsMedication Event Monitoring SystemEvent Monitoring SystemFirst monthMedication complianceSchizoaffective disorderCompliance rateTypical antipsychotic treatmentMean compliance ratePsychiatric inpatient hospitalHospital readmission dataElectronic monitoring devicesConsecutive patientsMedication regimensMonth 3Antipsychotic treatmentReadmission dataInpatient hospitalPatientsMEMS capsSchizophrenic disordersBottle openingHospitalSchizophreniaMonthsDisorders
1999
California Verbal Learning Test practice effects in a schizophrenia sample
Hawkins K, Wexler B. California Verbal Learning Test practice effects in a schizophrenia sample. Schizophrenia Research 1999, 39: 73-78. PMID: 10480669, DOI: 10.1016/s0920-9964(99)00015-8.Peer-Reviewed Original ResearchConceptsPractice effectsCalifornia Verbal Learning TestVerbal Learning TestTest practice effectsLearning TestWeek 10Sample of personsNew learningSchizophrenia sampleLater performancePrior exposureNon-pharmacological interventionsSerial performanceSample of patientsClinical circumstancesWeek 14Psychiatric statusLearningSchizophreniaCVLTExact natureMemoryConsiderable retentionLarge effectExposureWill the novel antipsychotics significantly ameliorate neuropsychological deficits and improve adaptive functioning in schizophrenia?
HAWKINS KA, MOHAMED S, WOODS SW. Will the novel antipsychotics significantly ameliorate neuropsychological deficits and improve adaptive functioning in schizophrenia? Psychological Medicine 1999, 29: 1-8. PMID: 10077288, DOI: 10.1017/s0033291798006990.Peer-Reviewed Original ResearchConceptsNovel antipsychoticsNegative symptomsNeuropsychological deficitsSevere psychiatric illnessNew antipsychotic medicationsTreatment of schizophreniaCognitive outcome dataAntipsychotic medicationConventional neurolepticsNeurodevelopmental aberrationsClinical effectivenessNew antipsychoticsUnderlying pathophysiologyClinical reasonsPsychiatric illnessImproved complianceOutcome dataFunctional capacityNeurological effectsAntipsychoticsAuditory hallucinationsNeurocognitive changesMedicationsNeural tissueSymptoms
1997
Normal neurocognitive performance after extended practice in patients with schizophrenia
Wexler B, Hawkins K, Rounsaville B, Anderson M, Sernyak M, Green M. Normal neurocognitive performance after extended practice in patients with schizophrenia. Schizophrenia Research 1997, 26: 173-180. PMID: 9323348, DOI: 10.1016/s0920-9964(97)00053-4.Peer-Reviewed Original ResearchConceptsWeeks of practiceSpecific neurocognitive tasksNormal neurocognitive performancePerformance of patientsImplicit learningMemory taskNeurocognitive tasksNeurocognitive performanceExtended practiceSame taskMotor tasksNeurocognitive improvementDifficulty levelOngoing instructionPerformance declineBase payTaskSupranormal performanceSchizophreniaHealthy controlsMemoryLearningInstructionTrainingPerformanceMemory deficits in schizophrenia: inadequate assimilation or true amnesia? Findings from the Wechsler Memory Scale--revised.
Hawkins KA, Sullivan TE, Choi EJ. Memory deficits in schizophrenia: inadequate assimilation or true amnesia? Findings from the Wechsler Memory Scale--revised. Journal Of Psychiatry And Neuroscience 1997, 22: 169-79. PMID: 9183115, PMCID: PMC1188849.Peer-Reviewed Original ResearchConceptsMemory deficitsWechsler Memory Scale-RevisedMedial temporal lobe structuresTemporal lobe structuresSchizophrenia spectrum patientsHippocampal dysfunctionSchizophrenia patientsTrue amnesiaWechsler Memory ScalePatientsImpaired attentionLobe structuresWechsler Adult Intelligence Scale-RevisedPsychiatric controlsSchizophreniaDysfunctionMemory ScaleDeficitsMemory testFindingsCognition, negative symptoms, and diagnosis: a comparison of schizophrenic, bipolar, and control samples
Hawkins KA, Hoffman RE, Quinlan DM, Rakfeldt J, Docherty NM, Sledge WH. Cognition, negative symptoms, and diagnosis: a comparison of schizophrenic, bipolar, and control samples. Journal Of Neuropsychiatry 1997, 9: 81-89. PMID: 9017533, DOI: 10.1176/jnp.9.1.81.Peer-Reviewed Original Research